ASND NASDAQ
Ascendis Pharma A/S
1W: -0.9%
1M: +0.4%
3M: +4.8%
YTD: +13.2%
1Y: +50.5%
3Y: +149.9%
5Y: +89.7%
$241.34
+3.36 (+1.41%)
Weekly Expected Move ±6.1%
$211
$226
$240
$255
$270
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.9B
52W Range153.49-250.74
Volume448,699
Avg Volume678,891
Beta0.41
Dividend—
Analyst Ratings
Company Info
CEOJan Moller Mikkelsen
Employees1,017
SectorHealthcare
IndustryBiotechnology
IPO Date2015-01-28
Websiteascendispharma.com
Tuborg Boulevard 12
Hellerup 2900
DK
Hellerup 2900
DK
45 70 22 22 44
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 Ã/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| JENSEN FLEMMING STEE | S-Sale | 19,460 | $238.49 | 2026-05-11 |
| BIENAIME JEAN JACQUE | 0 | — | 2026-03-23 | |
| BIENAIME JEAN JACQUE | 9,160 | $172.35 | 2026-03-23 | |
| Fairey William | 0 | — | 2026-03-18 | |
| Fairey William | 9,160 | $102.70 | 2026-03-18 |